Menu
Search
|

Menu

Close
X

Insmed Inc INSM.OQ (NASDAQ Stock Exchange Global Select Market)

25.09 USD
-0.32 (-1.26%)
As of 4:00 PM EDT
chart
Previous Close 25.41
Open 25.28
Volume 149,797
3m Avg Volume 244,421
Today’s High 25.28
Today’s Low 24.40
52 Week High 33.94
52 Week Low 11.49
Shares Outstanding (mil) 76.62
Market Capitalization (mil) 1,963.85
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.89 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.894
FY17
-2.865
FY16
-2.848
FY15
-2.025
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.86
Price to Sales (TTM)
vs sector
--
8.16
Price to Book (MRQ)
vs sector
4.48
4.20
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
69.61
17.38
LT Debt to Equity (MRQ)
vs sector
69.61
13.24
Return on Investment (TTM)
vs sector
-48.87
13.13
Return on Equity (TTM)
vs sector
-80.41
15.07

EXECUTIVE LEADERSHIP

Donald Hayden
Non-Executive Chairman of the Board, Since 2012
Salary: --
Bonus: --
William Lewis
President, Chief Executive Officer, Director, Since 2012
Salary: $550,000.00
Bonus: --
Paolo Tombesi
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
S. Nicole Schaeffer
Senior Vice President- Human Resource and Corporate Services, Since 2013
Salary: $322,301.00
Bonus: --
Walter Perkins
Chief Technology Officer, Since 2010
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10 Finderne Ave Bldg 10
BRIDGEWATER   NJ   08807-3365

Phone: +1908.9779900

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.

SPONSORED STORIES